106 related articles for article (PubMed ID: 2633926)
1. Metabolic disposition of ajmaline.
Köppel C; Tenczer J; Arndt I
Eur J Drug Metab Pharmacokinet; 1989; 14(4):309-16. PubMed ID: 2633926
[TBL] [Abstract][Full Text] [Related]
2. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Brøsen K; Gram LF; Kragh-Sørensen P
Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
[TBL] [Abstract][Full Text] [Related]
3. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
[TBL] [Abstract][Full Text] [Related]
4. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.
Irshaid YM; al-Hadidi HF; Latif A; Awwadi F; al-Zoubi M; Rawashdeh NM
Eur J Drug Metab Pharmacokinet; 1996; 21(4):301-7. PubMed ID: 9074894
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of dextromethorphan O-demethylation in man.
Küpfer A; Schmid B; Pfaff G
Xenobiotica; 1986 May; 16(5):421-33. PubMed ID: 3739367
[TBL] [Abstract][Full Text] [Related]
6. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
Schellens JH; Ghabrial H; van der Wart HH; Bakker EN; Wilkinson GR; Breimer DD
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):520-8. PubMed ID: 1934865
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse.
Iven H
Naunyn Schmiedebergs Arch Pharmacol; 1977 May; 298(1):43-50. PubMed ID: 882146
[TBL] [Abstract][Full Text] [Related]
9. Effect of sparteine and quinidine on the metabolism of methoxyphenamine by Cunninghamella bainieri.
Foster BC; Wilson DL; McGilveray IJ
Xenobiotica; 1989 Apr; 19(4):445-52. PubMed ID: 2750204
[TBL] [Abstract][Full Text] [Related]
10. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.
Zekorn C; Achtert G; Hausleiter HJ; Moon CH; Eichelbaum M
Klin Wochenschr; 1985 Nov; 63(22):1180-6. PubMed ID: 4079282
[TBL] [Abstract][Full Text] [Related]
12. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
13. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
14. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
Tyndale RF; Inaba T; Kalow W
Drug Metab Dispos; 1989; 17(3):334-40. PubMed ID: 2568917
[TBL] [Abstract][Full Text] [Related]
15. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
Turgeon J; Fiset C; Giguère R; Gilbert M; Moerike K; Rouleau JR; Kroemer HK; Eichelbaum M; Grech-Bélanger O; Bélanger PM
J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
[TBL] [Abstract][Full Text] [Related]
16. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
18. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
[TBL] [Abstract][Full Text] [Related]
19. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
20. Interaction of ethanol, quinidine, and sparteine with the metabolism of nifedipine by Cunninghamella echinulata.
Foster BC; Wilson DL; McGilveray IJ
Biopharm Drug Dispos; 1990 Nov; 11(8):735-8. PubMed ID: 2271749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
